A Study of Local Administration of Autologous Mesenchymal Stromal Cells in Dysphonic Patients With Vocal Fold Scarring

Phase 1

• Conditions: Dysphonia; Vocal Fold; Scar; Hoarseness; Aphonia
• Interventions: Biological: MSC-KI-PL-204

• Registration Number: NCT04290182
• Lead Sponsor: Karolinska University Hospital

Brief Summary

The overall aim of the project is to develop a new method for treatment of untreatable severe hoarseness due to vocal fold scarring by local injection of autologous mesenchymal stromal cells (MSC). At present there is no lasting effective treatment for this condition which results in personal suffering, and often extended sick leave, change of work or unemployement for the patients.

Based on the previous results the investigators expect the autologous MSC product KI-MSC-PL-204 to be a new effective treatment without side effects for many patients with severe hoarseness or aphonia due to vocal fold scarring.

Detailed Description

The general aim of the project is to develop a treatment for severe hoarseness due to vocal fold (VF) scarring. Vocal fold scarring can be caused by tumor surgery, radiotherapy, severe inflammation or is early acquired (sulcus vocalis with scar) and results in stiff vocal folds with decreased vibratory capacity and severe deterioration or total loss of voice (aphonia). There is no lasting effective treatment. Bone marrow derived mesenchymal stem cells (MSC) are immunomodulatory, decrease inflammation and improve endogenous healing. After receiving ethical permission the investigators have since 2012 treated 16 patients with manifest vocal fold scarring and severe hoarseness by scar resection and local injection of autologous bone marrow MSC to restore speech. This project was the first in the world to study the effects of MSC treatment of vocal fold scarring in humans. Analysis was made before and up to 12 months post operatively with voice recordings, examination with high speed camera and elasticity measurements of the vocal folds with novel technology. No side effects were found for any patient and for two thirds of the patients with 12 months follow-up the vocal fold function improved and no patient deteriorated.

While cell therapy with autologous MSC was classified according to the Tissue Legislation before 2015, it is now regarded as drug treatment. In accordance with this legislation, the MSC production is now full scale GMP. The investigators have recently received permissions from Swedish Medical Product Agency (DNr 5.1-2019-92069) and from the Regional ethic committee (Drn 2019-06160) for an open Phase I/Il study in patients with severe dysphonia and vocal fold scarring to evaluate safety, tolerability and vocal function after surgery with local administration of autologous mesenchymal stromal cell product KI-MSC-PL-204 as an extended study on 15 patients.

MSC may in the future be used to treat patients with severe hoarseness due to scarring, as well as other damages in the airways.

Study Timeline

• Status Verified: 2020-02
• Study First Submitted: 2020-02-25
• Study First Submitted QC: 2020-02-26
• Last Update Submitted: 2020-02-26
• Study First Posted: 2020-02-28
• Last Update Posted: 2020-02-28
• Study Start: 2020-03
• Primary Completion: 2022-06
• Study Completion: 2023-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Patients between 18-65 years with VF scarring and severe voice problems, such as permanent severe hoarseness, complete aphonia or severe voice strain during speech (>1 year) where other treatments have proven ineffective and no alternative treatment is possible.
• No alternative treatment ongoing or planned (phonosurgery with augmentation implantation, voice therapy or other medical treatment).

Exclusion Criteria

• Active treatment of laryngeal disorder, inflammatory condition of the larynx, or laryngeal/VF papilloma.
• Diagnosed or suspicion of local malignancy or other malignancies, Disease-free period of >5 years after malignant disease (>10 years for local laryngeal cancer).
• Smokers.
• Large scar defects.
• Pregnant or nursing (lactating) women.
• Serological evidence of infection with HIV, HBV, HCV, HTLV and/or syphilis.
• Active ongoing local or systemic infections.
• Ongoing immune suppressive treatment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single arm: MSC administration to vocal fold scar	MSC-KI-PL-204	1 single arm: Local injection of autologus MSC product (KI-MSC-PL-204) into scarred vocal fold (0,5-1 million cellls/Vocal fold, maximum 2 million cells if bilateral vocal fold scar)

Primary Outcome Measures

Name	Time	Method
Safety and tolerability of treatment	1 year	Number of serious adverse events or adverse events
Assessment of VF function	1 year	Assessment of VF function, as evaluated by high speed laryngeal/stroboscopy recordings, phonation threshold pressure and acoustic and perceptual voice analysis.
Assessment of subjective voice ratings	1 year	Assessment of patient´s subjective VHI ratings
Assessment of tissue metabolism and healing	1 year	Assessment of VF healing with PET-CT scans

Trial Locations

Locations (1)

Karolinska Trial Alliance; 🇸🇪 Stockholm, Sweden